ArticleBMC biotechnology2025
Green biosynthesis and antimicrobial activity of silver nanoparticles synthesized by Lactobacillus acidophilus against multidrug-resistant Klebsiella pneumoniae.
Article in BMC biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Development of durable sulfur nanoparticle-based antifungal coatings for cotton fabrics.RSC advances · 2026Article
- Ultrasound-assisted assembly ofFood chemistry: X · 2026Article
- HarnessingInternational journal of nanomedicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe rising global issue of antimicrobial resistance requires an immediate investigation of new antibacterial agents. This study examined the green biosynthesis of silver nanoparticles (BS-AgNPs) using the probiotic bacterium L. acidophilus (L. acidophilus) as a sustainable method to combat drug-resistant K. pneumoniae.
methodsThe MDR strains were screened, and the morphological properties of the resultant nanoparticles were evaluated using FESEM, DLS, and FTIR. The efficiency of bacterial virulence properties was investigated. Antibacterial experiments, including well diffusion, time-kill, and minimum inhibitory concentration (MIC) tests, were conducted. RT-qPCR evaluated the transcription of the mrkA and mrkD genes, which are critical for fimbrial synthesis and biofilm formation.
resultsBS-AgNPs were spherical with a median core size of 117 nm and a surface charge of − 1.2 mV. FTIR spectra revealed prominent peaks at 1634 cm⁻¹ (amide I) and 3311 cm⁻¹ (O–H/N–H stretch), confirming the role of L. acidophilus biomolecules as capping and reducing agents. The nanoparticles showed strong antibacterial efficacy, with MIC values of 1.56–3.125 µg/mL and MBC values of 6.25–12.5 µg/mL. Zones of inhibition ranged from 19 to 33 mm across different strains. Time-kill assays showed a rapid, dose-dependent reduction in bacterial load. RT-qPCR analysis indicated significant downregulation of mrkA and mrkD expression (p ≤ 0.05) in treated isolates.
conclusionThese findings highlight BS-AgNPs as a potent and eco-friendly therapeutic agent against virulent, multidrug-resistant K. pneumoniae infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.